PT1335728E - Novas preparacoes farmaceuticas compostas com base em sais do tiotropio e sais do salmeterol - Google Patents

Novas preparacoes farmaceuticas compostas com base em sais do tiotropio e sais do salmeterol

Info

Publication number
PT1335728E
PT1335728E PT01989446T PT01989446T PT1335728E PT 1335728 E PT1335728 E PT 1335728E PT 01989446 T PT01989446 T PT 01989446T PT 01989446 T PT01989446 T PT 01989446T PT 1335728 E PT1335728 E PT 1335728E
Authority
PT
Portugal
Prior art keywords
salts
salmeterol
tiotropy
pharmaceutical preparations
new compound
Prior art date
Application number
PT01989446T
Other languages
English (en)
Inventor
Schmelzer Christel
Nagel Juergen
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PT1335728E publication Critical patent/PT1335728E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT01989446T 2000-11-13 2001-11-09 Novas preparacoes farmaceuticas compostas com base em sais do tiotropio e sais do salmeterol PT1335728E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10056104A DE10056104A1 (de) 2000-11-13 2000-11-13 Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols

Publications (1)

Publication Number Publication Date
PT1335728E true PT1335728E (pt) 2005-05-31

Family

ID=7663071

Family Applications (2)

Application Number Title Priority Date Filing Date
PT01989446T PT1335728E (pt) 2000-11-13 2001-11-09 Novas preparacoes farmaceuticas compostas com base em sais do tiotropio e sais do salmeterol
PT04028508T PT1514546E (pt) 2000-11-13 2001-11-09 Composições medicamentosas à base de sais de tiotrópio e de sais de salmeterol

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT04028508T PT1514546E (pt) 2000-11-13 2001-11-09 Composições medicamentosas à base de sais de tiotrópio e de sais de salmeterol

Country Status (32)

Country Link
EP (3) EP1514546B1 (pt)
JP (2) JP4282322B2 (pt)
KR (2) KR100886094B1 (pt)
CN (1) CN1678318A (pt)
AT (2) ATE291428T1 (pt)
AU (3) AU2791002A (pt)
BG (1) BG107781A (pt)
BR (1) BR0115226A (pt)
CA (1) CA2429012A1 (pt)
CY (1) CY1106774T1 (pt)
CZ (1) CZ20031444A3 (pt)
DE (3) DE10056104A1 (pt)
DK (2) DK1335728T3 (pt)
EA (1) EA007904B1 (pt)
EC (1) ECSP034571A (pt)
EE (1) EE200300228A (pt)
ES (2) ES2240549T3 (pt)
HR (1) HRP20030378A2 (pt)
HU (1) HUP0301447A3 (pt)
IL (2) IL155718A0 (pt)
MX (1) MXPA03004164A (pt)
NO (1) NO20032111L (pt)
NZ (1) NZ526400A (pt)
PL (1) PL205330B1 (pt)
PT (2) PT1335728E (pt)
RS (2) RS20090105A (pt)
SG (1) SG167657A1 (pt)
SI (2) SI1335728T1 (pt)
SK (2) SK286950B6 (pt)
UA (1) UA74853C2 (pt)
WO (1) WO2002038154A1 (pt)
ZA (1) ZA200302921B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
EP1523976A3 (en) * 1999-11-23 2005-06-22 Glaxo Group Limited Pharmaceutical formulations of salmeterol
WO2003024452A1 (de) * 2001-09-14 2003-03-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittel zur inhalation
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
DE10256080A1 (de) * 2002-11-29 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropiumhaltige Arzneimittelkombination für die Inhalation
CN1726038A (zh) * 2002-12-16 2006-01-25 贝林格尔英格海姆法玛两合公司 含有噻托铵的hfc溶液剂
DE10351663A1 (de) * 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat
DE10345065A1 (de) * 2003-09-26 2005-04-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum
SG149876A1 (en) * 2003-11-03 2009-02-27 Boehringer Ingelheim Int Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
SG137859A1 (en) * 2003-11-03 2007-12-28 Boehringer Ingelheim Int Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
ATE474601T1 (de) * 2004-05-31 2010-08-15 Almirall Sa Kombinationen mit antimuskarin-wirkstoffen und pde4-hemmern
CN101166738B (zh) 2005-05-02 2011-06-01 贝林格尔·英格海姆国际有限公司 噻托溴铵的新晶型
WO2007017437A1 (en) * 2005-08-06 2007-02-15 Boehringer Ingelheim International Gmbh Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US20120220557A1 (en) * 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
JP6335798B2 (ja) * 2012-02-28 2018-05-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規噴射剤含有チオトロピウム製剤
WO2015065222A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Фармацевтический ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких, содержащий в качестве активного вещества микронизированный тиотропия бромид, и способ его получения
TW201835041A (zh) 2017-02-17 2018-10-01 印度商托仁特生技有限公司 具β-腎上腺素促效劑及抗蕈毒活性化合物
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
CN116196298A (zh) * 2018-07-26 2023-06-02 四川海思科制药有限公司 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用
WO2020019952A1 (zh) * 2018-07-26 2020-01-30 四川海思科制药有限公司 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
US11642372B2 (en) 2020-05-01 2023-05-09 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US11826382B2 (en) 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
WO2022119661A1 (en) * 2020-12-04 2022-06-09 Tygrus, LLC THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59911149D1 (de) * 1998-07-24 2004-12-30 Jago Res Ag Muttenz Medizinische aerosolformulierungen
DE19835346A1 (de) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
DE19847970A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähige Wirkstoff-Formulierung
DE19847971A1 (de) * 1998-10-17 1999-09-02 Schiering Verfahren und Einrichtung zur Verhinderung von Filterbränden (Staubfilter)
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator

Also Published As

Publication number Publication date
SK7412003A3 (en) 2003-10-07
EA007904B1 (ru) 2007-02-27
CY1106774T1 (el) 2012-05-23
NO20032111L (no) 2003-07-08
BR0115226A (pt) 2003-10-07
RS20090105A (en) 2009-07-15
ECSP034571A (es) 2003-06-25
KR100940752B1 (ko) 2010-02-11
YU35503A (sh) 2006-05-25
EP1514546A1 (de) 2005-03-16
PL205330B1 (pl) 2010-04-30
SK286939B6 (sk) 2009-07-06
PL365989A1 (en) 2005-01-24
DE50105729D1 (de) 2005-04-28
CZ20031444A3 (cs) 2003-08-13
SG167657A1 (en) 2011-01-28
ES2287629T3 (es) 2007-12-16
DK1514546T3 (da) 2007-09-24
JP4282594B2 (ja) 2009-06-24
AU2002227910B2 (en) 2007-03-01
EP1808174A1 (de) 2007-07-18
RS50286B (sr) 2009-09-08
NZ526400A (en) 2005-09-30
IL155718A (en) 2010-06-30
AU2007202303B2 (en) 2010-01-21
JP2004513146A (ja) 2004-04-30
CN1678318A (zh) 2005-10-05
EP1514546B1 (de) 2007-05-23
MXPA03004164A (es) 2005-08-16
SK286950B6 (sk) 2009-08-06
PT1514546E (pt) 2007-06-15
EE200300228A (et) 2003-10-15
CA2429012A1 (en) 2002-05-16
ES2240549T3 (es) 2005-10-16
JP4282322B2 (ja) 2009-06-17
AU2007202303A1 (en) 2007-06-14
KR100886094B1 (ko) 2009-02-27
DK1335728T3 (da) 2005-04-18
ZA200302921B (en) 2004-04-19
HUP0301447A2 (hu) 2003-10-28
BG107781A (bg) 2004-06-30
ATE362761T1 (de) 2007-06-15
NO20032111D0 (no) 2003-05-12
SI1335728T1 (en) 2005-08-31
EA200300503A1 (ru) 2004-12-30
KR20030065509A (ko) 2003-08-06
HUP0301447A3 (en) 2007-10-29
JP2005068163A (ja) 2005-03-17
IL155718A0 (en) 2003-11-23
HRP20030378A2 (en) 2005-04-30
EP1335728A1 (de) 2003-08-20
ATE291428T1 (de) 2005-04-15
AU2791002A (en) 2002-05-21
KR20080079701A (ko) 2008-09-01
WO2002038154A1 (de) 2002-05-16
SI1514546T1 (sl) 2007-10-31
EP1335728B1 (de) 2005-03-23
DE10056104A1 (de) 2002-05-23
UA74853C2 (en) 2006-02-15
DE50112535D1 (de) 2007-07-05

Similar Documents

Publication Publication Date Title
PT1335728E (pt) Novas preparacoes farmaceuticas compostas com base em sais do tiotropio e sais do salmeterol
RS50269B (sr) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I β-MIMETIKA
YU6303A (sh) Nova heterociklična jedinjenja, njihovo dobijanje i njihova upotreba kao medikamenata, a naročito kao anti-bakterijskih agenasa
NO20022334D0 (no) Ny sammensetning og anvendelse
NO20051259L (no) Biaryl-diazabicykloalkanamider som nikotinacetylcholinagonister
NO20045486L (no) Nye forbindelser og deres anvendelse
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
BR0210912A (pt) Compostos e composições como inibidores de catepsina
SE0102440D0 (sv) New compound
DE60225694D1 (de) Fexofenadine hydrochlorid polymorph
SE0102057D0 (sv) New Salts I
TW200517146A (en) Novel composition
ATE374203T1 (de) Therapeutische verbindungen und verfahren
EE200300419A (et) R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina
AR037967A1 (es) Utilizacion de desoxipeganina en el tratamiento de la depresion clinica
PE20020525A1 (es) Composiciones que comprende sales de tiotropio y agentes antihistaminicos
SE0102058D0 (sv) New Salts II
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
NO20000199D0 (no) Medikamenter inneholdende polyhydroksybutylpyraziner, nye polyhydroksybutylpyraziner og deres fremstilling
ATE298564T1 (de) Arzneimittelformulierung enthaltend einen ltb4 antagonisten und einen netzmittel
IT1318650B1 (it) 1,3-diossolani ad attivita' antitosse.
DK1370529T3 (da) Substituerede dimethyl-[-1(1-phenyl-cyclohexyl)-piperidin-3-ylmethyl]-aminer og anvendelse som analgetika
MX9708072A (es) Combinacion de un inhibidor de la incorporacion de 5-ht con un antagonista 5-ht 1a selectivo.